RecruitingPhase 3NCT07473973

ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency

The ENERGY 2 Study: An Open-Label Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Infants With Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

Sponsor

Inozyme Pharma

Enrollment

12 participants

Start Date

Mar 26, 2025

Study Type

INTERVENTIONAL

Conditions

Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency Autosomal Recessive Hypophosphatemic Rickets Generalized Arterial Calcification of Infancy 1

Summary

The primary purpose of ENERGY 2 (Study INZ701-105) is to assess the efficacy and safety of INZ-701 in infants with ENPP1 Deficiency.

Eligibility

Min Age: 0 YearsMax Age: 1 Year

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called INZ-701 for people with autosomal recessive hypophosphatemic rickets, ectonucleotide pyrophosphatase/phosphodiesterase1 deficiency, and other related conditions. The study is currently recruiting participants at 8 locations. People eligible for this study include aged 0 Years to 1 Year.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGINZ-701

Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.

Locations(8)

Hospital Universitario Pedro Ernesto/Rio de Janeiro

Rio de Janeiro, Brazil

Hopital Necker - Enfants Malades

Paris, France

Gyermekgyogyaszat, DE

Debrecen, Hungary

Azienda Ospedaliera Universitaria Meyer

Florence, Italy

King Faisal Specialist Hospital and Research Center

Riyadh, Saudi Arabia

Hospital Sant Joan de Deu Edificio Consultas Externas. Unitat de Recerca

Barcelona, Esplugues de Llobregat, Spain

Umraniye Traiing and Research Hospital

Istanbul, Turkey (Türkiye)

Royal Manchester Children's Hospital

Manchester, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07473973

Related Trials

The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency

NCT057341967 locations

ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency

NCT064625475 locations